Results 241 to 250 of about 396,778 (337)

Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling

open access: yesAdvanced Science, EarlyView.
Cer24:1 levels are reduced in neutrophilic asthma and inversely correlate with disease severity and airway neutrophilia. Restoring Cer24:1 suppresses pathogenic Th17 differentiation by engaging EP2 on CD4+ T cells, thereby dampening the JAK2–STAT3–RORγt axis and reducing IL‐17 production.
Huan Liu   +11 more
wiley   +1 more source

Effects of MMP-1 1G/2G polymorphism on osteoarthritis: A meta-analysis study

open access: green, 2019
Bo Xu   +5 more
openalex   +2 more sources

Neutrophil‐Driven Cascade‐Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia–Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
A neutrophil‐mediated dual‐targeting liposome (NKN‐LNP) is developed to treat renal ischemia–reperfusion injury. The system enables spatiotemporally controlled delivery of NMN to injured tubules via MMP‐2/9 activation and KIM1 recognition, restoring mitochondrial function through NAD+‐SIRT3 signaling and preventing the transition from acute kidney ...
Hangbin Ma   +15 more
wiley   +1 more source

Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis

open access: yesAdvanced Science, EarlyView.
Considering the great challenge in Glioblastoma multiforme (GBM) treatment, the authors designed and synthesized a multifunctional nanoplatform that effectively induced ferroptosis by synergetically inhibiting intrinsic intrisinc anti‐ferroptosis proteins, GPX4 & DHODH, and realized excellent in vitro and in vivo anti‐GBM effect.
Guodong Ren   +12 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

open access: yesAdvanced Science, EarlyView.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy